Metabolic & Cardiometabolic
ezetimibe treats sitosterolemia
In plain terms: Does ezetimibe treat the rare disease sitosterolemia?
Strong support Metabolic & Cardiometabolic
Part of: 💊 ezetimibe
RefutedContestedStrong support
consensus score 0.97
Yes, it blocks the plant-cholesterol over-absorption that defines the disease and is the treatment of choice.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
25 support 0 contradict 0 tested null 1 mixed · 26 sources, 25 independent groups
What the evidence shows
Ezetimibe is the drug of choice for sitosterolemia (ABCG5/G8 plant-sterol hyperabsorption) - it blocks the NPC1L1-mediated hyperabsorption that defines the disease. Its one definitive non-LDL indication. (Clinically relevant mainly where statin-poorly-responsive hypercholesterolemia + xanthomas raise suspicion of sitosterolemia.)
The evidence (30)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Castellanos AA, Castillo MDC, Montoya L, Ruiz ME, Zapateiro JL, Nogueira JP 2024 · Clin Investig Arterioscler | observational | supports | low | Clinical note on the first two familial sitosterolemia patients reported in Colombia, brothers at a hospital in Monteria. Genetic testing found a pathogenic homozygous ABCG8 variant in the older brother, whose only symptom was xanthomas on his limbs, and a heterozygous ABCG8 variant in his completely asymptomatic brother. Only the symptomatic brother was treated, and the authors say he 'has responded to treatment with ezetimibe'. The paper does not report any cholesterol or plant-sterol values, the dose, or how long he was followed. |
| Do TTM, Vu CD, Dien TM, Can TBN, Nguyen TTN, Nguyen HH, Tran VK, Nguyen NL, Tran HT, Mai TTC, Nguyen KN 2025 · J Clin Med | observational | supports | low | Retrospective review of 14 Vietnamese children with genetically confirmed sitosterolemia at one Hanoi hospital, 2015-2024. After three months on a low-plant-sterol diet alone (n=10), total and LDL cholesterol fell but not significantly (p=0.093 and p=0.059), so ten were escalated to drug therapy. That drug was ezetimibe or cholestyramine, and the paper never says how many children got which, so there is no ezetimibe-only result. Among the eight treated over three months, median total cholesterol fell 54.9% and LDL-C 67.3% (p=0.012). Plant-sterol levels were never measured. |
| Umapathy V, Rm S 2025 · J Assoc Physicians India | observational | supports | low | Case series of four patients with sitosterolemia in Trichy, India, who presented with nonspecific symptoms and thrombocytopenia rather than xanthomas. Every patient had stomatocytes and macrothrombocytes on peripheral blood smear, and sequencing found an ABCG5 mutation in two and ABCG8 in the other two. None had xanthomas or liver disease. 'All of them responded to a low plant sterol diet and ezetimibe.' The report gives no cholesterol or plant-sterol values, no dose and no follow-up duration, and the sterol-restricted diet ran alongside the drug in all four. |
| Naeem WB, Khan MA, Akram Z, Afridi TUK, Khattak TA, Khan MA, Yousaf M, Satti HS 2025 · J Clin Lipidol | observational | supports | low | Two siblings from a consanguineous Pakistani family, found during a workup for hereditary hemolytic anemia, carried a previously unreported homozygous ABCG5 variant (c.274A>G, p.Lys92Glu). Both had anemia, gum bleeding, easy bruising, stomatocytes and macrothrombocytopenia, and plasma sitosterol of 27.7 and 25.1 mg/dL confirmed sitosterolemia. Ezetimibe lowered both sitosterol and LDL-cholesterol in the two patients, but the report gives no post-treatment values, no percentage change and no treatment duration. |
| Kassaie H, Cheawsamoot C, Kanchanasutthiyakorn S, Santawong K, Chomtho S, Thangpong R, Shotelersuk V 2025 · Biomed Rep | observational | supports | low | 15-year-old with homozygous ABCG5 variant and 13 years of therapy-resistant hypercholesterolemia; after introducing dietary phytosterol restriction and ezetimibe, lipid levels normalized within 4 months. |
| Trehan M, Agrawal R, Nayak AR, Dhawan R, Dass J, Kumar G, Kumar P, Chauhan R, Seth T, Mahapatra M, Aggarwal M 2026 · Indian J Hematol Blood Transfus | observational | supports | low | Four patients aged 10 to 29 came to a New Delhi haematology clinic with haemolytic anaemia and no signs of high cholesterol; their blood smears showed stomatocytes and large platelets with low platelet counts, and sequencing found ABCG5 or ABCG8 mutations confirming sitosterolemia. Three were started on ezetimibe together with a low-plant-sterol diet and 'have shown significant hemoglobin improvement'; the fourth had only just begun. The abstract gives no haemoglobin, cholesterol or plant-sterol values before or after treatment and no follow-up time, and the diet ran alongside the drug. |
| Huang S, Du M, Wang X, Liu Y, Song F 2025 · Translational Pediatrics | observational | supports | low | Retrospective series of 12 Chinese children with sitosterolemia, followed 1 to 8 years. Nine were managed by low-phytosterol diet alone; only three took ezetimibe (5 mg/day plus cholestyramine for 12 months; 2.5 mg/day for 24 months; 5 mg/day for 6 months) after diet alone proved insufficient. In those three, total cholesterol fell from 76.92, 22.1 and 10.5 to 16.63, 4.71 and 5.95 mmol/L and LDL-C from 74.37, 16.39 and 9.25 to 8.74, 2.22 and 4.52 mmol/L, with no side effects seen. Plant sterols were measured only before treatment, so the paper does not report their change. |
| Donnelly A, Leary FO, Veitch K, McElnea E 2026 · Cornea | observational | supports | low | A 9-year-old girl was referred for an arcus in her right cornea and a discrete lipid deposit in her left. Serum cholesterol was 12 mmol/L (normal 3-5) and LDL 10.8 mmol/L (normal below 3), and genetic testing found a pathogenic ABCG5 variant confirming sitosterolemia. Her cholesterol and lipid profile returned to normal after plant-sterol dietary restriction plus ezetimibe 10 mg and atorvastatin 10 mg daily. One patient, three treatments started together; the paper gives no numbers after treatment and never reports her plant-sterol levels. |
| Wu SF, Xu ZY, Xie LJ, Chen L, Ye Y, Wang XL, Zou J, Zhu J, Wang RL, Luo YJ, Zhang JH, Chen Q, Ruan DD, Zhou YF, Gao MZ, Zhang L, Li YF, Fang ZT, Huang FM, Liao LS, Hu B, Zheng ZH, Luo JW, Lin XF 2026 · J Chromatogr B Analyt Technol Biomed Life Sci | observational | supports | low | Whole-exome sequencing in a 3-year-old girl with xanthomas since age 2 found a compound heterozygous ABCG5 mutation: c.1337G>A (p.Arg446Gln) from her father, likely pathogenic, and c.1396G>C (p.Ala466Pro) from her mother, of uncertain significance. Plasma sterol profiling showed elevated campesterol, stigmasterol, sitosterol and cholestanol with normal squalene and lathosterol. Ezetimibe with a low-plant-sterol diet improved her xanthomas and biochemical parameters; the diet ran alongside the drug and no lipid or sterol value after treatment began is reported. One patient, no control group. |
| Gu R, Wang H, Wang CL, Lu M, Miao M, Huang MN, Chen Y, Dai YL, Zhu MQ, Zhou Q, Zou CC 2024 · Lipids Health Dis | observational | supports | low | Retrospective series of 26 Chinese children with sitosterolemia (2013-2023). Eleven (42.3%) were treated with ezetimibe, alone or with another lipid-lowering drug; 13 (50.0%) with diet alone; one each with simvastatin or cholestyramine. Total cholesterol (13.36 mmol/L on average before treatment) and LDL-C (5.98 mmol/L) fell markedly afterwards (P < 0.0001), usually within 3 to 6 months. That comparison pools everyone treated, so the paper does not say how much of the fall belonged to ezetimibe rather than diet, and a few patients still had high sitosterol on ezetimibe plus strict diet. |
| Lütjohann D, von Bergmann K, Sirah W, Macdonell G, Johnson-Levonas AO, Shah A, Lin J, Sapre A, Musliner T 2008 · Int J Clin Pract | observational | supports | moderate | Two-year open-label extension of an 8-week randomised, placebo-controlled base study in homozygous sitosterolemia (base study: 4:1 to ezetimibe 10 mg/day n=30 or placebo n=7); in the extension every patient took open-label ezetimibe 10 mg/day on background resins, statins and low-sterol diet. Among the 21 completing the second extension, mean change from baseline was sitosterol -43.9% and campesterol -50.8% (p<0.001), LDL sterols -13.1%, total sterols -10.3%, apoB -10.1% (p<0.050); reductions were maximal by week 52 but for LDL sterol, total sterols and apoB 'waned slightly'. No control arm. |
| Coutinho JGV, Costa ACS, Issa MMM, Paim NP, Quedas EPS, Nunes VS, Jorge AAL, Nakandakare ER, Carrilho AJF 2025 · J Clin Lipidol | observational | supports | low | A Brazilian man diagnosed with sitosterolemia at 23 was followed for 21 years on a low-plant-sterol diet plus ezetimibe. Over that time he had 'resolution of splenomegaly and thrombocytopenia, stabilization or reduction in xanthoma growth, and absence of cardiovascular events', though plasma campesterol and beta-sitosterol stayed above normal. Genetic testing found two ABCG5 variants, c.64C>T p.(Gln22) and c.1217G>A p.(Arg406Gln), and the authors argue the second is pathogenic. One patient, no control group, and the sterol-restricted diet ran alongside the drug. |
| Salen G, von Bergmann K, Lutjohann D, Kwiterovich P, Kane J, Patel SB, Musliner T, Stein P, Musser B, Multicenter Sitosterolemia Study Group 2004 · Circulation | RCT | supports | high | Multicenter, double-blind, placebo-controlled RCT in sitosterolemia. After a 3-week placebo run-in, '37 patients were randomized to receive placebo (n=7) or ezetimibe 10 mg/d (n=30) for 8 weeks.' In the ezetimibe arm 'sitosterol concentrations decreased by 21% (P<0.001)' versus 'a nonsignificant 4% rise' on placebo (between-group P<0.001); campesterol fell a mean 24% with ezetimibe vs a 3% increase with placebo. Reductions were similar with or without concomitant resin or statin. Endpoints were plasma sterols and apolipoprotein B, not clinical events. |
| Wu LL, Zhang L, Tang TT, Zhou YY, Chang XX, Guo W, Yan HM, Lin HD 2026 · J Med Case Rep | observational | supports | low | A 29-year-old Chinese man with statin-refractory hypercholesterolemia and childhood xanthomas carried two ABCG5 mutations, c.1256G>A (p.Arg419His) and c.751C>T (p.Gln251). On a statin in May 2023 his total cholesterol was 8.16 and LDL-C 5.28 mmol/L; after starting ezetimibe 10 mg daily with a strict low-cholesterol, low-plant-sterol diet, both normalized within 2 months. The diet ran alongside the drug. The authors never measured his plasma sterols before treatment, and at follow-up his beta-sitosterol was still 246.08 umol/L against a reference of 3.74-14.58. One patient, no control group. |
| Burke E, O'Meara M, McGrath N, Griffin D 2026 · Pediatrics | observational | supports | low | A 7-year-old girl presented after surgical removal of a corneal lipid keratopathy, with tuberous xanthomas on her knuckles and knees. Total cholesterol was 11.9 mmol/L and LDL 10.2 mmol/L. She responded only partially to a statin; familial hypercholesterolemia genetic testing was negative and an expanded panel found compound heterozygous ABCG5 variants, with markedly elevated phytosterols. She was treated with a low-plant-sterol diet plus ezetimibe. A CT coronary angiogram showed no coronary artery calcification. The paper reports no lipid or sterol values after treatment began. |
| Noreña Gómez SI et al 2026 · Research Square (preprint, not peer-reviewed; under review at Journal of Rare Diseases, revision requested 2026-03-26) | observational | supports | low | Single case report of an 8-year-old boy with two trans compound heterozygous ABCG8 variants: c.647_657dup p.(Arg220Valfs37) (pathogenic) and c.1720G>C p.(Gly574Arg) (likely pathogenic). Ezetimibe plus a plant-sterol-restricted diet started July 2023, when total cholesterol was 253 mg/dL and LDL 194 mg/dL; by February 2024 these were 177 and 113 mg/dL (December 2022, untreated: 305 and 248). Plasma phytosterols were never measured - the authors cite 'the inability to quantify plasma phytosterols' - so the documented response is a cholesterol response, with diet given alongside the drug. |
| Gamage D, Chisholm K, Kilo T, Ooi SE, Srinivasan S 2025 · Journal of Paediatrics and Child Health | observational | supports | low | Case series of 4 Australian children (18 months-18 years) with genetically confirmed sitosterolaemia, all given ezetimibe 10 mg daily plus a low plant sterol diet. The two with high baseline cholesterol fell sharply: total cholesterol 16.3 to 4.6 mmol/L and LDL 13.4 to 2.4 in one, 8.5 to 4.7 and 4.6 to 3.1 in the other. The two presenting with blood abnormalities improved on blood film, one's haemolytic anaemia resolving with a normal platelet count, though the other's LDL rose 3.5 to 4.0 mmol/L. Uncontrolled, diet given alongside the drug, and no follow-up plant sterol levels reported. |
| Uzunyayla G, Erdem-Karapinar F, Isat E, Cansever MS 2025 · J Clin Lipidol | observational | supports | low | Single case report of a 6-year-old Turkish girl found to have sitosterolemia after isolated thrombocytopenia turned up at a routine school screening. Her plasma plant sterols were markedly elevated but she had no dyslipidemia and no xanthomas, and genetic testing found a homozygous pathogenic ABCG5 variant (c.161G>A, p.Trp54Ter). On ezetimibe her platelet count rose from 58,000/mm3 before treatment to 117,000/mm3 after therapy and 140,000/mm3 at the latest follow-up. The report gives no post-treatment plant sterol values, no dose and no treatment duration; one patient, no control. |
| Matta A, Nader V, Ferrières D, Ferrières J 2026 · Am J Prev Cardiol | observational | supports | low | A 61-year-old woman treated as homozygous familial hypercholesterolemia for over 50 years (total cholesterol 680 mg/dl in childhood, tendinous xanthomas) in fact had sitosterolemia: plasma sitosterol 465 µmol/L (upper limit 8) and campesterol 242 µmol/L (upper limit 10.6), two pathogenic ABCG5 variants, and a negative familial-hypercholesterolemia gene panel. Ezetimibe 10 mg lowered her total cholesterol to 269 mg/dl and LDL-C to 188 mg/dl, and the authors report her hematologic abnormalities improved on it. Her plant-sterol levels before versus during ezetimibe are not reported. |
| Maidman SD, Gurevitz C, Rosenson RS 2025 · JACC Case Reports | observational | supports | low | Single case report. A 45-year-old man with childhood xanthomas and untreated LDL cholesterol of 481 mg/dL carried one LDLR variant and one ABCG8 variant, with beta-sitosterol and campesterol about twice the reference range. Already on rosuvastatin 40 mg plus evolocumab (LDL 117 mg/dL), he added ezetimibe 10 mg daily together with plant-sterol restriction and a low-saturated-fat diet; LDL fell to 51 mg/dL, a further 56%. Diet ran alongside the drug, plant sterol levels were not re-measured afterwards, and the authors say this ABCG8 variant's pathogenicity is classified inconsistently. |
| Patel PS, Paknikar S, Simha V 2025 · J Clin Lipidol | observational | supports | low | Three adult siblings (42, 39 and 35 years) with chronic unexplained thrombocytopenia, all long misdiagnosed as immune thrombocytopenic purpura, turned out to carry homozygous ABCG5 mutations; the index case's LDL cholesterol was 121 mg/dL and none had clinical cardiovascular disease. All three started ezetimibe 10 mg daily together with a diet limiting plant sterols. After 3 to 6 months sitosterol fell 40% to 51% and campesterol 40% to 66%, and platelet counts rose 22% to 39%. Three patients in one family, no control group, and the diet ran alongside the drug. |
| Alves AC, Chora JR, Miranda B, Medeiros AM, Graça R, Bañares VG, Araujo MB, Vilagut FT, Soler C, Meavilla S, Toledo MJB, Volpe CG, Reyes X, Dell'Oca N, Martins P, Marado D, Vilarinho L, Dias AJ, Ferreira AC, Padeira G, Casañas M, Alegre-González D, Lozano JM, Aguiar P, Gonçalves FS, Ernaga A, Apellaniz-Ruiz M, Rubi R, Figueroa NM, Vasquez NA, Valdivielso P, Bourbon M 2025 · J Clin Lipidol | observational | supports | low | Sixteen molecularly confirmed sitosterolemia cases from five Iberoamerican countries (12 index cases, 4 relatives found by cascade screening): 15 had biallelic ABCG8 variants and 1 a homozygous ABCG5 frameshift. Xanthomas in 56%. Most had first been diagnosed as familial hypercholesterolemia, with a diagnostic delay of up to 30 years. In this uncontrolled case series, ezetimibe - alone or combined with a statin - was followed by biochemical and clinical improvement, including xanthoma regression in some cases. |
| Hummadi A, Mutawwam DA, Banaganapalli B, Alsubhi F, Aljohani NJ, Alhagawy AJ, Algohani T, Fallatah I, Daghriry MY, Alharbi RK, Alhafaf H, Talal M, Hassan RR 2025 · Frontiers in Genetics | observational | supports | low | A Saudi family carrying a heterozygous LDLR frameshift and a single pathogenic ABCG8 splice variant. Plant sterols were never measured, so sitosterolemia was never confirmed, and one ABCG8 allele is a carrier state for a recessive disease. The 55-year-old index case was already on rosuvastatin 40 mg plus evolocumab when ezetimibe was added, and his LDL fell from 5.1 to 1.9 mmol/L - add-on, not monotherapy. His son and daughter did take ezetimibe alone; the authors report LDL unchanged at 3 months, while their own table shows falls from 6.95 to 4.68 and 7.27 to 5.24 mmol/L. |
| Mustajoki S, Sinisalo M, Jernman J, Sipila K, Nevalainen PI 2026 · J Clin Lipidol 2026 Jun;20(6):1271-1276 | observational | supports | low | Single-patient case report (2026). A 30-year-old man with phytosterolemia confirmed by 'a pathogenic homozygous variant, c.1083G>A (p.Trp361Ter), in the ABCG8 gene', with coronary artery disease and a histiocytic tumor. 'Avoiding dietary plant sterols, in combination with ezetimibe and rosuvastatin, effectively corrected dyslipidemia' - statin and diet ran alongside, so ezetimibe's own contribution is not separable, and the paper does not report lipid or plant-sterol values. Inflammation persisted: CRP and ESR 'remained elevated' until tocilizumab was added. n=1, uncontrolled. |
| Warang P, Dongerdiye R, Dehadrai P, Kamble P, Samanpalliwar N, Madkaikar M, Shanmukhaiah C, Kedar PS 2026 · Human Mutation | observational | mixed | low | Four Indian patients with confirmed sitosterolemia presenting as haemolytic anaemia; only two of them, sisters, took ezetimibe 10 mg/day for 6 months alongside a plant-sterol-restricted diet, and the other two were lost to follow-up. In the two treated, stigmasterol fell from 41.83 to 39.32 and 36.75 to 30.74 umol/L and beta-sitosterol from 19.43 to 15.55 and 17.04 to 13.56, but haemoglobin did not improve (8.0 to 7.9 and 8.1 to 6.3 g/dL), platelet counts fell, and the overhydrated red cell fraction showed only minimal improvement. Uncontrolled, two patients, diet alongside the drug. |
| Del Castillo J, Tool ATJ, van Leeuwen K, van Alphen FPJ, Brands MM, Suijker MH, Meijer AB, Hoogendijk AJ, Kuijpers TW 2024 · Blood Advances | observational | supports | low | Four children from two unrelated consanguineous pedigrees with homozygous ABCG5 sitosterolemia, first misdiagnosed as immune thrombocytopenia, took ezetimibe with a sterol-poor diet for about a year. Plasma sitosterol fell significantly (P = 1.81 x 10^-7) and platelet counts rose (P = .017), the two inversely correlated (Pearson -0.63); treatment 'reduced lipid levels to subnormal concentrations while normalizing hematologic parameters'. The sterol-poor diet ran alongside, so ezetimibe's own share is not separable, and with n=4 and no control arm this is an uncontrolled before-after series. |
| Othman RA, Myrie SB, Mymin D, Merkens LS, Roullet JB, Steiner RD, Jones PJ 2014 · J Clin Lipidol | observational | supports | moderate | Single-site pilot, 8 related Hutterite sitosterolemia patients (homozygous ABCG8 S107X), 14 wk off then 14 wk on ezetimibe 10 mg; no control. On EZE: plasma sitosterol −35 ± 4%, total plant sterols −37 ± 4% (mean ± SEM, P < .0001); platelets +23% vs off phase (170 vs 144 ×10^3/µL, P = .03); MPV −10% measured vs baseline only (off-phase MPV lost, baseline n = 5). Plasma TC −12% (P = .09). Not generalisable beyond this genotype (authors). |
| Leão FAA, Silveira LFG, Arantes RR, Guimarães MMM 2025 · Arch Endocrinol Metab | observational | supports | low | Single case report of a Brazilian man homozygous for the ABCG8 nonsense mutation p.Trp361, diagnosed only in 2018 after 13 years treated as cerebrotendinous xanthomatosis and a heart attack at 27. On a plant-sterol-restricted diet plus ezetimibe he showed 'good clinical and metabolic response and an increment in platelet count': total cholesterol fell from 243 mg/dL in 2005 to 132 by 2023 and LDL-cholesterol from 177 to 56, and a 2021 coronary CT showed no new plaques. Rosuvastatin was continued alongside, and plasma phytosterols were never measured in this patient. |
| Waluś-Miarka M, Nogieć A, Fedak A, Malone C, Khalil Y, Clayton PT, Chyrchel B, Małecki MT, Humphries SE 2026 · J Clin Lipidol | observational | supports | low | A 19-year-old Polish man with severe statin-resistant hypercholesterolemia had total cholesterol 8.0 mmol/L, LDL 5.80 mmol/L and triglycerides 2.38 mmol/L. Sequencing found two ABCG8 variants, a pathogenic c.1083G>A (p.Trp361Ter) from his father and c.1534G>A (p.Gly512Arg) of uncertain significance from his mother, both also in his brother. Serum sitosterol was 333.9 umol/L and campesterol 139.8 umol/L. Ezetimibe plus a low-plant-sterol diet improved his lipid profile; the paper reports no lipid or sterol value after treatment began. One patient, no control group, diet alongside the drug. |
| Anum, Bavli NR, Ahmad Z 2025 · JCEM Case Rep | observational | supports | low | A 61-year-old man with sitosterolemia caused by a novel pair of ABCG8 variants was started on ezetimibe 10 mg daily on top of rosuvastatin 5 mg and a low-plant-sterol diet. Over 9 months his sitosterol fell from 374.4 to 199.8 mg/L and campesterol from 189.6 to 97.5 mg/L (normal is under 15.0 and 8.0), LDL cholesterol from 126 to 98 mg/dL and haemoglobin from 11.5 to 13.4 g/dL. His platelet count barely moved, 75,000 to 85,000/uL, and the authors call the sterol fall modest, under 50%. One patient, no control, three treatments started together. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.